MedPath

Boehringer Ingelheim USA Corporation

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Postmarketing Surveillance Study With MOBEC®

Completed
Conditions
Osteoarthritis
Interventions
Drug: MOBEC
First Posted Date
2014-07-08
Last Posted Date
2014-07-09
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
4760
Registration Number
NCT02182726

Bioavailability of BI 1356 After Single Oral Administration Given as Different Tablet Formulation in Healthy Male Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BI 1356 - Tablet TFII
Drug: BI 1356 - Tablet iFF
Drug: BI 1356 - Tablet TFIIb
First Posted Date
2014-07-08
Last Posted Date
2014-07-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
24
Registration Number
NCT02183363

Bioavailability of BI 1356 After Co-administration With Ritonavir Compared to the Bioavailability of BI 1356 Alone in Healthy Male Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2014-07-08
Last Posted Date
2014-07-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
12
Registration Number
NCT02183441

Efficacy and Safety Study of Meloxicam Versus Mefenamic Acid in Patients With Dysmenorrhea

Phase 2
Completed
Conditions
Dysmenorrhea
Interventions
Drug: Placebo matching 7.5 mg meloxicam
Drug: Placebo matching 500 mg mefenamic acid
Drug: Placebo matching 15 mg meloxicam
First Posted Date
2014-07-08
Last Posted Date
2018-08-31
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
337
Registration Number
NCT02183025

Effect of BI 1356 as Single Dose on the QT Interval in Healthy Female and Male Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BI 1356, high dose
Drug: BI 1356, low dose
Drug: Placebo
First Posted Date
2014-07-08
Last Posted Date
2014-07-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
44
Registration Number
NCT02183467

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS in Patients With Type 2 Diabetes

Phase 1
Completed
Conditions
Diabetes Mellitus, Type 2
Interventions
Drug: BI 1356 BS - single rising dose
Drug: Placebo
First Posted Date
2014-07-08
Last Posted Date
2014-07-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
47
Registration Number
NCT02183350

Study to Assess the Efficacy and Safety of Meloxicam vs. Diclofenac SR in Patients With Osteoarthritis of the Knee

Phase 4
Completed
Conditions
Osteoarthritis
Interventions
First Posted Date
2014-07-08
Last Posted Date
2023-11-24
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
91
Registration Number
NCT02183129

Efficacy and Safety of Oral Treatment With BIBF 1120 ES in Advanced Non-small-cell Lung Cancer

Phase 2
Completed
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Drug: BIBF 1120 ES high dose
Drug: Placebo to BIBF 1120 ES
Drug: BIBF 1120 ES low dose
First Posted Date
2014-07-08
Last Posted Date
2017-12-28
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
73
Registration Number
NCT02182050

Evaluation of Efficacy and Safety of Meloxicam Suppository (15mg Daily) and Tablet (15 mg Daily) Compared to Indomethacin Suppository (50 mg Daily) in Patients With Ankylosing Spondylitis

Phase 3
Completed
Conditions
Spondylitis, Ankylosing
Interventions
First Posted Date
2014-07-08
Last Posted Date
2023-11-24
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
192
Registration Number
NCT02183168

An Dose Escalation Study of BIBF 1120 Administered in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1
Completed
Conditions
Multiple Myeloma
Interventions
Drug: BIBF 1120 ES
First Posted Date
2014-07-08
Last Posted Date
2014-07-18
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
17
Registration Number
NCT02182141
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy